FI2124547T4 - Syövän hoitomenetelmä - Google Patents

Syövän hoitomenetelmä

Info

Publication number
FI2124547T4
FI2124547T4 FIEP08729939.2T FI08729939T FI2124547T4 FI 2124547 T4 FI2124547 T4 FI 2124547T4 FI 08729939 T FI08729939 T FI 08729939T FI 2124547 T4 FI2124547 T4 FI 2124547T4
Authority
FI
Finland
Prior art keywords
cancer
use according
leukemia
treatment
lymphoma
Prior art date
Application number
FIEP08729939.2T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Connie Erickson-Miller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI2124547(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI2124547T4 publication Critical patent/FI2124547T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP08729939.2T 2007-02-16 2008-02-15 Syövän hoitomenetelmä FI2124547T4 (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (1)

Publication Number Publication Date
FI2124547T4 true FI2124547T4 (fi) 2025-07-29

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP08729939.2T FI2124547T4 (fi) 2007-02-16 2008-02-15 Syövän hoitomenetelmä

Country Status (28)

Country Link
US (2) US20100075928A1 (OSRAM)
EP (1) EP2124547B3 (OSRAM)
JP (1) JP5511391B2 (OSRAM)
KR (1) KR101447763B1 (OSRAM)
CN (1) CN101662937B (OSRAM)
AR (1) AR065348A1 (OSRAM)
AU (1) AU2008216106C1 (OSRAM)
BR (1) BRPI0807940B8 (OSRAM)
CA (1) CA2678358C (OSRAM)
CR (1) CR10997A (OSRAM)
DK (1) DK2124547T6 (OSRAM)
EA (1) EA017715B1 (OSRAM)
ES (1) ES2675070T7 (OSRAM)
FI (1) FI2124547T4 (OSRAM)
HU (1) HUE038563T2 (OSRAM)
IL (2) IL200319A (OSRAM)
MA (1) MA31202B1 (OSRAM)
MX (1) MX2009008822A (OSRAM)
NZ (1) NZ579068A (OSRAM)
PE (1) PE20081784A1 (OSRAM)
PL (1) PL2124547T5 (OSRAM)
PT (1) PT2124547T (OSRAM)
SI (1) SI2124547T2 (OSRAM)
TR (1) TR201809010T4 (OSRAM)
TW (1) TW200906393A (OSRAM)
UY (1) UY30915A1 (OSRAM)
WO (1) WO2008101141A2 (OSRAM)
ZA (1) ZA200905532B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
IL262746B (en) * 2016-05-06 2022-09-01 Taris Biomedical Llc A method for treating urothelial cancer in the lower system
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
WO2001007423A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
CA2390095C (en) * 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
EP1284997B1 (en) * 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
ATE486859T1 (de) 2004-10-25 2010-11-15 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
AU2006318527A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
BRPI0709286A2 (pt) 2006-03-15 2011-07-05 Ligand Pharm Inc processo de sìntese de compostos para modulção da atividade da trombopoietina

Also Published As

Publication number Publication date
EP2124547B3 (en) 2025-06-18
US20100075928A1 (en) 2010-03-25
AR065348A1 (es) 2009-06-03
SI2124547T1 (en) 2018-08-31
CN101662937A (zh) 2010-03-03
DK2124547T6 (da) 2025-09-01
IL200319A (en) 2015-05-31
AU2008216106C1 (en) 2025-11-13
SI2124547T2 (sl) 2025-07-31
IL238394B (en) 2018-05-31
DK2124547T3 (en) 2018-07-16
CA2678358A1 (en) 2008-08-21
BRPI0807940B1 (pt) 2020-10-27
WO2008101141A3 (en) 2008-10-16
HUE038563T2 (hu) 2018-10-29
AU2008216106B9 (en) 2013-09-05
PL2124547T3 (pl) 2018-08-31
PE20081784A1 (es) 2009-01-25
NZ579068A (en) 2012-05-25
EP2124547A4 (en) 2010-05-05
JP2010519221A (ja) 2010-06-03
EP2124547B2 (en) 2025-04-16
AU2008216106B2 (en) 2013-07-11
AU2008216106A1 (en) 2008-08-21
ES2675070T3 (es) 2018-07-06
TR201809010T4 (tr) 2018-07-23
CA2678358C (en) 2015-12-08
IL238394A0 (en) 2015-06-30
EP2124547A2 (en) 2009-12-02
BRPI0807940B8 (pt) 2021-05-25
BRPI0807940A2 (pt) 2013-07-30
MX2009008822A (es) 2009-08-28
JP5511391B2 (ja) 2014-06-04
WO2008101141A2 (en) 2008-08-21
CN101662937B (zh) 2014-03-12
PT2124547T (pt) 2018-07-04
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
EP2124547B1 (en) 2018-03-28
EA200970776A1 (ru) 2010-02-26
CR10997A (es) 2009-10-16
DK2124547T4 (da) 2025-08-04
KR101447763B1 (ko) 2014-10-07
UY30915A1 (es) 2008-09-02
ZA200905532B (en) 2010-04-28
TW200906393A (en) 2009-02-16
EA017715B1 (ru) 2013-02-28
IL200319A0 (en) 2010-04-29
ES2675070T7 (en) 2025-08-06
MA31202B1 (fr) 2010-02-01
PL2124547T5 (pl) 2025-08-04

Similar Documents

Publication Publication Date Title
FI2124547T4 (fi) Syövän hoitomenetelmä
JP2011126896A5 (OSRAM)
Zhang et al. Targeting the Wnt/β-catenin signaling pathway in cancer
Alanazi et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
Cao et al. Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: a novel class of potent tubulin polymerization inhibitors
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
Hagras et al. Discovery of new quinolines as potent colchicine binding site inhibitors: Design, synthesis, docking studies, and anti-proliferative evaluation
Eldehna et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents
Bérubé An overview of molecular hybrids in drug discovery
Negi et al. Strategies to reduce the on‐target platelet toxicity of Bcl‐xL inhibitors: PROTACs, SNIPERs and prodrug‐based approaches
KR101345002B1 (ko) 제약 화합물
JP2010518110A5 (OSRAM)
Yadav et al. The recent development of tetrahydro-quinoline/isoquinoline based compounds as anticancer agents
JP2010528026A5 (OSRAM)
AU2012322660B2 (en) Pyrazol-3-ones that activate pro-apoptotic BAX
AU2013235425B2 (en) Inhibition of MCL-1 and/or BFL-1/A1
JP2009516653A5 (OSRAM)
HRP20140790T1 (hr) Inhibitori aktivnosti akt
AU2013302766B2 (en) Benzodiazepines for treating small cell lung cancer
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
JPWO2021085653A5 (OSRAM)
JP2010519221A5 (OSRAM)
JP2014530881A5 (OSRAM)
JP2013504582A5 (OSRAM)
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1